Clinical trial
A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Controlled Ovarian Stimulation in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
NCT01922193 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Controlled Ovarian Stimulation in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
- Lead sponsor
- Ferring Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2013
- Completion date
- April 30, 2015
- Enrollment
- 263 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.